579MO CheckMate 9KD cohort A2 final analysis: Nivolumab (NIVO) + rucaparib for chemotherapy (CT)-naïve metastatic castration-resistant prostate cancer (mCRPC)
Daniel P. Petrylak, José Luis Perez‐Gracia, Louis Lacombe, Diogo Assed Bastos, Hakim Mahammedi, Edmond M. Kwan, Stefanie Zschäbitz, Andrew J. Armstrong, Russell K. Pachynski, Jeffrey C. Goh, Mauricio Burotto, Gwénaëlle Gravis, Steve McCune, Juan Carlos Vázquez Limón, Margitta Retz, Fred Saad, Neha P. Amin, Jianqing Li, Keziban Ünsal-Kaçmaz, Karim Fizazi
Topics & Concepts
MedicineEnzalutamideInternal medicineCohortProstate cancerOncologyNivolumabAnemiaDocetaxelCancerImmunotherapyAndrogen receptorProstate Cancer Treatment and ResearchPARP inhibition in cancer therapyCancer Immunotherapy and Biomarkers